首页> 美国卫生研究院文献>World Journal of Gastroenterology >Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells
【2h】

Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells

机译:小干扰RNA和拉米夫定联合抑制人B病毒在HepG2.2.15细胞中的复制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To observe the inhibition of hepatitis B virus (HBV) replication and expression by combination of siRNA and lamivudine in HepG2.2.15 cells.METHODS: Recombinant plasmid psil-HBV was constructed and transfected into HepG2.2.15 cells. The transfected cells were cultured in lamivudine-containing medium (0.05 μmol/L) and harvested at 48, 72 and 96 h. The concentration of HBeAg and HBsAg was determined using ELISA. HBV DNA replication was examined by real-time PCR and the level of HBV mRNA was measured by RT-PCR.RESULTS: In HepG2.2.15 cells treated with combination of siRNA and lamivudine, the secretion of HBeAg and HBsAg into the supernatant was found to be inhibited by 91.80% and 82.40% (2.89 ± 0.48 vs 11.73 ± 0.38, P < 0.05; 4.59 ± 0.57 vs 16.25 ± 0.48, P < 0.05) at 96 h, respectively; the number of HBV DNA copies within culture medium was also significantly decreased at 96 h (1.04 ± 0.26 vs 8.35 ± 0.33, P < 0.05). Moreover, mRNA concentration in HepG2.2.15 cells treated with combination of siRNA and lamivudine was obviously lower compared to those treated either with siRNA or lamivudine (19.44 ± 0.17 vs 33.27 ± 0.21 or 79.9 ± 0.13, P < 0.05).CONCLUSION: Combination of siRNA and lamivudine is more effective in inhibiting HBV replication as compared to the single use of siRNA or lamivudine in HepG2.2.15 cells.
机译:目的:观察siRNA和拉米夫定联合对HepG2.2.15细胞对乙肝病毒(HBV)复制和表达的抑制作用。方法:构建重组质粒psil-HBV并转染HepG2.2.15细胞。将转染的细胞在含拉米夫定的培养基(0.05μmol/ L)中培养,并在48、72和96 h收获。使用ELISA测定HBeAg和HBsAg的浓度。结果:在经siRNA和拉米夫定联合处理的HepG2.2.15细胞中,发现HBeAg和HBsAg分泌到上清液中,从而检测到HBV DNA的复制,RT-PCR检测HBV mRNA的水平。在96 h分别被抑制91.80%和82.40%(2.89±0.48 vs 11.73±0.38,P <0.05; 4.59±0.57 vs 16.25±0.48,P <0.05);培养基中HBV DNA拷贝数在96 h时也显着减少(1.04±0.26 vs 8.35±0.33,P <0.05)。此外,与siRNA或拉米夫定联合处理的HepG2.2.15细胞中的mRNA浓度明显低于siRNA或拉米夫定联合处理的细胞(19.44±0.17 vs 33.27±0.21或79.9±0.13,P <0.05)。与在HepG2.2.15细胞中单次使用siRNA或拉米夫定相比,siRNA和拉米夫定在抑制HBV复制方面更为有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号